OncoSynergy and our lead therapeutic program, OS2966, were featured in an ‘Emerging Company Profile’ in BioCentury, The Bernstein Report on BioBusiness.
See pdf 061614_ECP_OncoSynergy
The Bernstein Report is the flagship weekly publication of BioCentury Publications, Inc. providing analysis and commentary on the biopharma industry.
OS2966 is currently under development for the treatment of orphan cancers with high unmet need. A Phase I clinical trial is being planned for glioblastoma, the most common and malignant brain tumor in adults.
Please contact us at email@example.com for more information.